NEW JERSEY REGISTER
VOLUME 35, NUMBER 13
MONDAY, JULY 7, 2003
RULE ADOPTION
LAW AND PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
STATE BOARD OF MEDICAL EXAMINERS
Limitations On Prescribing, Administering Or Dispensing Of
Controlled Substances;
Special Exceptions For Management Of Pain Implantable Infusion
Pumps
Adopted Amendment: N.J.A.C. 13:35-7.6
Proposed: October 7, 2002 at 34 N.J.R. 3441(a).
Adopted: February 19, 2003 by William V. Harrer, MD, President,
State Board of Medical Examiners.
Filed: June 10, 2003 as R.2003 d.263, without change.
Authority: N.J.S.A. 45:9-2.
Effective Date: July 7, 2003.
Expiration Date: September 20, 2004.
Summary of Public Comment and Agency Response:
The official comment period ended December 6, 2002. The Board
received no comments.
Federal Standards Statement
A Federal standards analysis is not required because there
are no Federal standards or requirements applicable to the adopted
amendment.
Full text of the adoption follows:
< < NJ ADC 13:35-7.6 > >
13:35-7.6 Limitations on prescribing, administering or dispensing
of controlled substances; special exceptions for management
of pain
(a)-(b) (No change.)
(c) A practitioner may exceed the 120 dosage unit or 30-day
supply limitations for Schedule II controlled substances in
(b) above in the following circumstances:
1. For the 120 dosage unit limitation, the practitioner follows
a treatment plan designed to achieve effective pain management
which has been tailored to the needs of a patient who is suffering
pain from cancer, intractable pain or terminal illness. The
treatment plan shall state objectives by which treatment success
is to be evaluated, such as pain relief and improved physical
and psychological function, and shall indicate if any further
diagnostic evaluations or other treatments are planned. The
practitioner shall discuss the risks and benefits of the use
of controlled substances with the patient, guardian or authorized
representative; and
2. With regards to the 30-day supply limitation, a practitioner
may prescribe the use of an implantable infusion pump which
is utilized to achieve pain management for patients suffering
from cancer, intractable pain or terminal illness. A prescription
for such an implantable infusion pump may provide up to a
90-day supply as long as the physician evaluates and documents
the patient's continued need at least every 30 days.